HIV Clinical Trials Market to Grow Significantly Owing
to Increasing Global Burden of HIV/AIDS

The HIV clinical trials market involves various stages of
clinical research being conducted to develop new treatment strategies and drugs
for HIV/AIDS. The market consists of antiretroviral drugs, vaccines,
pre-exposure prophylaxis, microbicides, and other emerging therapeutics being
tested for the treatment and prevention of HIV infection. Significant research
investments and collaborations between drug manufacturers, academic
institutions, and non-profit organizations are being made to advance the
clinical development of novel HIV therapies.

Global HIV
clinical trials market is estimated to be valued at USD 1.48 Bn in 2024 and is
expected to reach USD 2.19 Bn by 2031, exhibiting a compound annual growth rate
(CAGR) of 5.7% from 2024 to 2031.

Key Takeaways



Key players operating in the HIV clinical trials market are Gilead Sciences,
Inc., Johnson & Johnson, Merck & Co. These leading pharmaceutical
companies are investing heavily in developing new classes of antiretroviral
drugs with improved efficacy and safety profiles. For instance, Gilead
Sciences' Biktarvy and Merck's Doravirine are some of the best-selling brands
in the market.



The growing burden of HIV/AIDS globally is driving increased HIV
Clinical Trials Market Growth for new treatment options. According to
UNAIDS, around 38 million people were living with HIV/AIDS worldwide in 2020,
underscoring the need for continual research on newer drugs and prevention
methods.



Technological advancements such as therapies targeting viral reservoirs and
gene therapy holds promise for a potential cure. Biotechs are exploring several
novel mechanisms of action beyond traditional antiretroviral drugs to achieve
long-term remission without lifelong treatment.



Market Trends



Growing Research on Long-Acting Injectables: Long-acting injectable
antiretrovirals administered every 2-3 months can improve treatment adherence
compared to daily oral pills. Drugs under evaluation include Cabotegravir,
Lenacapavir, and Islatravir.



Increased Focus on Developing Integrated Therapies: Combination therapies
integrating antiretrovirals with other agents such as cancer drugs,
anti-inflammatory, and gene therapies hold potential to achieve functional
cures.

Get More Insights On- HIV
Clinical Trials Market